TY - PAT
T1 - Selective Neural Nitric Oxide Synthase Inhibitors
AU - Silverman, Richard
N1 - filingdate: 2006-1-26
issueddate: 2008-12-30
Status: published
attorneydocketnumber: 2001-057-02
PY - 2008/12/30
Y1 - 2008/12/30
N2 - Inhibitors of Neuronal Nitric Oxide Synthase
NU 2001-057, 2003-083, 2005-128, 2008-172, 2008-179, 2009-024, 2009-164, 2010-008, 2010-075, 2011-053, 2012-112, 2012-146, 2013-020
Short description: A portfolio of neuronal nitric oxide synthase inhibitors for use in treating neurodegenerative disorders.
#therapeutics #CNS
Abstract:
Northwestern researchers have created a diverse portfolio of neuronal nitric oxide synthase (nNOS) inhibitors. These inhibitors are potent, selective and able to permeate the blood-brain barrier. These small molecules include enhanced chemical compositions, such as those created by heteroaromatic selection, aminopyridine dimers, chiral pyrrolidine cores, azole rings that facilitate heme binding, intramolecular hydrogen bonding, and thiophene-2-carboximidamide-based compounds. The methods for synthesis as well as the small molecules are patented or have patent applications under review. Specific information on the individual compositions is available on request.
Applications:
o Therapeutic for neurological disorders, such as:
o Stroke
o Schizophrenia
o Migraine Headaches
o Cerebral Ischemia
o Long-Term Depression
o Therapy for neurodegenerative disorders, such as Huntington's disease, Parkinson's disease and Alzheimer's disease
o Potential for use in other disorders where nNOS is a therapeutic target
Advantages:
o Variety of chemical compositions
o Potent
o Selective
o Bioavailable
o Permeate the blood-brain barrier
o Selectivity results in reduced side effects compared to general NOS inhibitors
Inventors:
Richard B. Silverman*
Hui Huang
Henry Qingwei Zhang
Erik Erdal
Jose Antonio Gomez Vidal
Jung-Mi Hah
Mark Flinspach
Haitao Mark Ji
Huiying Li
Thomas L. Poulos
Graham R. Lawton
Fengtian Xue
James M Kraus
He Huang
Qing Jing
IP Status:
Issued U.S. Patents: 7,470,815; 8,158,658; 7,470,790; 7,994,326; 7,994,326; 7,994,326; 8,299,100; 8,278,084; 8,389,731; 8,618,143; 8,697,879; 8,557,552; 8,735,606; 8,735,606. Additional U.S. patent applications have been filed.
International patent applications have also been filed.
AB - Inhibitors of Neuronal Nitric Oxide Synthase
NU 2001-057, 2003-083, 2005-128, 2008-172, 2008-179, 2009-024, 2009-164, 2010-008, 2010-075, 2011-053, 2012-112, 2012-146, 2013-020
Short description: A portfolio of neuronal nitric oxide synthase inhibitors for use in treating neurodegenerative disorders.
#therapeutics #CNS
Abstract:
Northwestern researchers have created a diverse portfolio of neuronal nitric oxide synthase (nNOS) inhibitors. These inhibitors are potent, selective and able to permeate the blood-brain barrier. These small molecules include enhanced chemical compositions, such as those created by heteroaromatic selection, aminopyridine dimers, chiral pyrrolidine cores, azole rings that facilitate heme binding, intramolecular hydrogen bonding, and thiophene-2-carboximidamide-based compounds. The methods for synthesis as well as the small molecules are patented or have patent applications under review. Specific information on the individual compositions is available on request.
Applications:
o Therapeutic for neurological disorders, such as:
o Stroke
o Schizophrenia
o Migraine Headaches
o Cerebral Ischemia
o Long-Term Depression
o Therapy for neurodegenerative disorders, such as Huntington's disease, Parkinson's disease and Alzheimer's disease
o Potential for use in other disorders where nNOS is a therapeutic target
Advantages:
o Variety of chemical compositions
o Potent
o Selective
o Bioavailable
o Permeate the blood-brain barrier
o Selectivity results in reduced side effects compared to general NOS inhibitors
Inventors:
Richard B. Silverman*
Hui Huang
Henry Qingwei Zhang
Erik Erdal
Jose Antonio Gomez Vidal
Jung-Mi Hah
Mark Flinspach
Haitao Mark Ji
Huiying Li
Thomas L. Poulos
Graham R. Lawton
Fengtian Xue
James M Kraus
He Huang
Qing Jing
IP Status:
Issued U.S. Patents: 7,470,815; 8,158,658; 7,470,790; 7,994,326; 7,994,326; 7,994,326; 8,299,100; 8,278,084; 8,389,731; 8,618,143; 8,697,879; 8,557,552; 8,735,606; 8,735,606. Additional U.S. patent applications have been filed.
International patent applications have also been filed.
M3 - Patent
M1 - 7470815
ER -